Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × tafasitamab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Mantle-Cell 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Lymphoma, B-Cell 3 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Recurrence 1 Leukemia, Prolymphocytic 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 101 Dexamethasone 54 Cytarabine 47 fludarabine phosphate 45 fludarabine 44 Rituximab 44 Gemcitabine 34 Peripheral Blood Stem Cell Transplantation 32 Lenalidomide 32 Etoposide 32 pembrolizumab 30 Radiotherapy 29 Filgrastim 29 Busulfan 28 Cyclosporine 26 Methotrexate 25 Melphalan 25 Carboplatin 25 Cisplatin 24 venetoclax 23 Mycophenolic Acid 23 Paclitaxel 22 Bortezomib 22 Whole-Body Irradiation 21 Granulocyte Colony-Stimulating Factor 20 Bevacizumab 20 Antilymphocyte Serum 19 Temozolomide 18 Oxaliplatin 17 Decitabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07126236 2025-08-17

REPIFIR

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡